Weight Loss

---

 Retatrutide is a novel investigational peptide developed by Eli Lilly that targets three key receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple agonist action differentiates Retatrutide from GLP-1 agonists like semaglutide (Ozempic) and tirzepatide (Mounjaro), which are dual agonists. By activating three metabolic pathways instead of one or two, Retatrutide may deliver superior results in fat loss, blood glucose control, and energy balance.